Press Releases
Flamel Technologies to Work with Connetics
Corporation on New Feasibility Study Utilizing Medusa, Flamel’s Patented Protein
Delivery Technology.
Lyon, France, Jan. 4,
2001 – Flamel Technologies S.A. announced today that it
has begun work on a new feasibility study utilizing Flamel's Medusa®
technology to provide controlled release delivery of relaxin, a recombinant form
of human protein developed by Connetics Corporation, which may serve as a
treatment for a variety of disorders, including peripheral arterial disease,
cardiovascular disease, infertility and other systemic diseases.
"We are pleased to add Connetics to our
growing list of partners for Flamel Technologies," said Dr. Gerard Soula, chief
executive officer of Flamel. "This new partnership is designed to show the
application of our proprietary protein and peptide delivery technology to an
additional protein. We hope that this study and others will continue to
demonstrate the wide ranging potential for our proprietary technology."
Flamel Technologies S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Flamel’s Medusa® nano-encapsulation technology is designed to deliver therapeutic proteins. Micropump® is a controlled release technology for the oral administration of small molecule drugs. Flamel’s expertise in polymer science has also been instrumental in the development of a photochromic eyeglass lens product now marketed by Corning Inc. Additionally, Flamel has developed new herbicide delivery systems now being tested by Monsanto and has patented a biomaterial, ColCys™.
This document contains a number of matters, particularly as related to the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel’s reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel’s Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 1999.
